Medication for Constipation

Marion Debus

Last update: 18.07.2019

  • In case of atony with too little propulsion:
    Bitter substances (e.g., Amara or Gentiana drops, see also https://www.anthromedics.org/PRA-0703-EN)

  • Especially with simultaneously occurring gas and bloating:
    Absinthium/Caryophylli comp. dil. WELEDA, 12 drops 3x/d
    Wormwood activates the peristalsis in the upper gastrointestinal tract, carnation seed essential oil has a warming effect, anise relaxes and regulates intestinal motility.

  • For constipation:
    Hepatodoron® tabs. WELEDA, 3x/d, chew 2–4 tabs. at the beginning of each meal

    Choleodoron® drops WELEDA, 10–20 drops 3x/d after meals

    Digestodoron® WELEDA, 3x/d, chew 2 tabs. at the beginning of each meal, or 15 drops 4x/d

  • In case of spastic constipation or chemotherapy-associated constipation (triggered by antiemetics from the serotonin antagonist family, whose symptoms can persist for several days, or even up to a week):
    Carpellum Mali comp. trit. WELEDA, 1 saltsp. (~¼ tsp.) 3–6/d after meals
    Start the day before chemotherapy with 1 generous salt spoon (or ¼ tsp.) to 1 teaspoon tip 3 x daily, then from the day of the chemotherapy onwards 1 generous salt spoon (~¼ tsp.) to 1 teaspoon tip 3–6 x daily. In the beginning it is more common to dose 6 x daily, then gradually reduce the amount, e.g., to 4 x daily, then 3 x daily, with dosing determined by stool frequency, whereby patients find their own dosage.

Research news

Case series: Topical application of Viscum album extract in keratinocyte carcinomas shows remissions 
A retrospective case series examined the safety and clinical effects of topical application of 10% lipophilic Viscum album extract (VALE) in individual cases of cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC) and actinic keratosis (AK). The study population consisted of 55 patients with 74 skin lesions. Risk factors, concomitant therapies and diseases, adverse drug reactions to VALE and other relevant information were documented. As a result, the clinical response rate was 78% for cSCC, 70% for BCC and 71% for AK. The complete remission rates for individual lesions were 56% for cSCC, 35% for BCC and 15% for AK. Overall, the results suggest that VALE is a safe and tolerable extract, and complete and partial remissions of ceratinocyte carcinomas were observed with its use. The article is published in Complementary Medicine Research: 
https://doi.org/10.1159/000537979.


Further information on Anthroposophic Medicine